Blocking an enzyme called indoleamine-2,3-dioxygenase 1 (IDO1) can rescue memory and brain function in models that mimic Alzheimer’s, Penn State researchers say. IDO1 inhibitors have already shown promise in the fight against melanoma, leukemia and breast cancer .
“We’re showing that there is high potential for IDO1 inhibitors, which are already within the repertoire of drugs being developed for cancer treatments, to target and treat Alzheimer’s,” said study co-author Melanie McReynolds , an assistant professor at Penn State.
A team from Penn State, Stanford University and other parts of the world found that stopping IDO1 helps restore healthy glucose metabolism in astrocytes, the most abundant cells in the human brain.
Glucose, a form of sugar, fuels many processes as the brain’s primary energy source. Low glucose levels can impair brain function and lead to seizures, loss of consciousness and even permanent brain damage.
“We’re demonstrating that by targeting the brain’s metabolism, we can not only slow, but reverse the progression of this disease,” explained Praveena Prasad , a Penn State doctoral student and co-author of the paper.
Get updates delivered to you daily. Free and customizable.
It’s essential to note our commitment to transparency:
Our Terms of Use acknowledge that our services may not always be error-free, and our Community Standards emphasize our discretion in enforcing policies. As a platform hosting over 100,000 pieces of content published daily, we cannot pre-vet content, but we strive to foster a dynamic environment for free expression and robust discourse through safety guardrails of human and AI moderation.
Comments / 0